당뇨병 치료제 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the diabetes drugs market size is expected to grow from USD 90.60 billion in 2025 to USD 93.79 billion in 2026 and is forecast to reach USD 111.5 billion by 2031 at 3.52% CAGR over 2026-2031.

This report is Segmented by Drug Class (Oral Anti-Diabetic Drugs [Biguanides, Alpha-Glucosidase Inhibitors, and More], Insulin, Non-Insulin Injectable Drugs, and Combination Drugs), Route of Administration (Oral, Subcutaneous, and Intravenous), Distribution Channel (Online Pharmacies, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Diabetes Drugs Market Trends and Insights

Escalating Global Diabetes Prevalence & Earlier Screening

The International Diabetes Federation logged 588.7 million adults with diabetes in 2024, up 45% from 2021, yet 251.7 million remain undiagnosed, creating large latent demand that mass screening in China, India and Gulf states is beginning to unlock. Africa shows the highest undiagnosed rate at 72.6%, while Asia-Pacific hosts 60% of total cases, concentrating growth where healthcare infrastructure is scaling quickly. Gulf Cooperation Council governments subsidize HbA1c testing and SGLT-2 reimbursement, a blueprint Indonesia and Pakistan now emulate to counter fast-growing type 2 incidence. Japan and South Korea weave HbA1c checks into employer health exams, pulling treatment initiation forward by roughly three years and extending lifetime drug exposure. As screening penetrates deeper, diagnosed prevalence rises faster than epidemiology alone, permanently enlarging the diabetes drugs market.

Rising Healthcare Expenditures in Emerging Markets

China's 2023 update to the National Reimbursement Drug List added semaglutide, dulaglutide, empagliflozin and dapagliflozin, unlocking coverage for 1.4 billion citizens and lifting GLP-1 prescriptions 68% year over year in top-tier cities. India earmarked USD 1.2 billion for 2024-2026 to fund district-level diabetes clinics and biosimilar insulin procurement, cutting patient out-of-pocket spending by 40% in pilot states. Brazil's public health system awarded glargine biosimilar contracts at 55% discounts to originators, a model Argentina and Colombia now replicate to stretch limited budgets. These moves convert cash-pay patients to reimbursed status, boosting volume for oral antidiabetics and biosimilar insulin. Asia-Pacific and Latin America together will represent roughly 80% of incremental diabetes drug spending through 2031, more than offsetting price pressure in North America and Europe.

Safety Concerns Regarding GLP-1-Linked Pancreatitis & Thyroid Risks

All GLP-1 agents carry boxed thyroid warnings in the United States, mirrored by European labels, dampening prescriptions for patients with relevant family history. A 2024 Nature Medicine review linked GLP-1 therapy to higher relative risks of pancreatitis, gallbladder disease and 15-20% early discontinuation from gastrointestinal intolerance, prompting label revisions and slower uptitration schedules. Litigation over delayed gastroparesis disclosures added further caution, elongating dose-escalation to mitigate side effects. The EMA opened a safety probe in 2025 after isolated suicidal-ideation reports, temporarily stalling new-patient starts in Germany and France. These issues weigh most heavily on obesity prescriptions, where benefit-risk calculus is less clear than in diabetes.

Other drivers and restraints analyzed in the detailed report include:

1. Strong Clinical Evidence & Guideline Endorsements for GLP-1 & SGLT-2 Classes
2. Growing Adoption of Biosimilar Basal Insulins
3. Public-Sector Insulin Price Caps & Tender-Based Procurement

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Insulin retained 56.56% of 2025 revenue, yet non-insulin injectables are expanding at a 4.25% CAGR through 2031, the strongest pace among all classes, as GLP-1 and dual agonists cannibalize basal insulin starts. Tirzepatide generated USD 3.1 billion in Q3 2024 alone, showcasing the commercial leverage of 15-20% weight-loss efficacy relative to single-agonist semaglutide's 5-10%. Oral SGLT-2 and DPP-4 inhibitors captured 28% of prescriptions, buoyed by multi-organ benefit data and generic DPP-4 availability. Combination agents such as Xultophy and Synjardy simplify regimens but remain reimbursement-constrained in cost-sensitive markets, limiting share to 8%.

Basal insulins saw double-digit volume erosion in mature regions as physicians delay initiation in favor of GLP-1s, while biosimilar glargine and degludec compress branded prices in Europe. Bolus insulins hold demand in type 1 diabetes, but even here faster-acting analogs like Fiasp gain share by improving post-meal control. Conventional human formulations still dominate low-income markets because they tolerate warmer storage and cost far less than analogs. Weekly insulins icodec and efsitora await U.S. clearance after European approval in 2024, with limited near-term impact on the diabetes drugs market size.

Complete Report Scope:

• By Drug Class
  • Oral Anti-Diabetic Drugs
    • Biguanides
    • Alpha-glucosidase Inhibitors
    • Dopamine-D2 Receptor Agonists
    • SGLT-2 Inhibitors
      • Canagliflozin (Invokana)
      • Empagliflozin (Jardiance)
      • Dapagliflozin (Farxiga/Forxiga)
      • Ipragliflozin (Suglat)
    • DPP-4 Inhibitors
      • Sitagliptin (Januvia)
      • Saxagliptin (Onglyza)
      • Linagliptin (Tradjenta)
      • Alogliptin (Nesina/Vipidia)
      • Vildagliptin (Galvus)
    • Sulfonylureas
    • Meglitinides
  • Insulin
    • Basal / Long-acting
      • Insulin Glargine (Lantus, Toujeo, Basaglar)
      • Insulin Detemir (Levemir)
      • Insulin Degludec (Tresiba)
    • Bolus / Fast-acting
      • Insulin Aspart (NovoRapid/Novolog)
      • Insulin Lispro (Humalog)
      • Insulin Glulisine (Apidra)
    • Traditional Human Insulin
      • Novolin / Actrapid / Insulatard
      • Humulin
      • Insuman
    • Biosimilar Insulin
      • Insulin Glargine Biosimilars
      • Human Insulin Biosimilars
    • Ultra-long-acting weekly analogues
  • Non-Insulin Injectable Drugs
    • GLP-1 Receptor Agonists
      • Liraglutide (Victoza)
      • Exenatide (Byetta, Bydureon)
      • Dulaglutide (Trulicity)
      • Lixisenatide (Lyxumia)
    • Dual & Triple Incretin Co-agonists
      • Tirzepatide (Mounjaro)
      • Retatrutide (Phase III)
    • Amylin Analog
  • Combination Drugs
    • Combination Insulin
      • Biphasic Insulin Aspart (NovoMix)
      • Insulin Degludec + Aspart (Ryzodeg)
      • Insulin Degludec + Liraglutide (Xultophy)
    • Oral Combination
      • Sitagliptin + Metformin (Janumet)
      • Empagliflozin + Metformin (Synjardy)
• By Route of Administration
  • Oral
  • Subcutaneous
  • Intravenous
• By Distribution Channel
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.13% of 2025 revenue but will trail the global growth average at a 2.8% CAGR amid price controls and biosimilar encroachment. U.S. list prices remain five-fold higher than Europe's, sustaining per-patient spend despite volume stagnation. Canada caps GLP-1 coverage with strict HbA1c thresholds, limiting uptake, while Mexico procures glargine at the world's lowest price via public tenders.

Asia-Pacific is the fastest-growing region at 5.51% CAGR to 2031, led by China's 140 million-patient pool and reimbursed access to modern agents. India's WHO-vetted biosimilars ship to 70 countries, positioning the country as the low-cost supply hub. Japan's DPP-4 dominance underscores differing clinical practice where low obesity reduces the urgency for weight-centric GLP-1s. South Korea's broad subsidy for insulin pumps and continuous glucose monitors fosters the world's highest closed-loop adoption rate.

Europe's share in 2025 masks diverging dynamics: biosimilar insulin already accounts for a notable share of volume, and mandatory substitution ensures further penetration. The Middle East and Africa capture a minor share of global revenue in 2025, concentrated in subsidized Gulf states, yet expatriate exclusion limits volume despite high prevalence. South America is similarly polarized: Brazil's public insulin coverage reaches 8 million patients, yet private-market GLP-1 access remains restricted to higher-income groups.

1. AstraZeneca
2. Biocon
3. Boehringer Ingelheim
4. Bristol-Myers Squibb
5. Eli Lilly and Company
6. Gan & Lee Pharmaceuticals
7. Hanmi Pharmaceutical
8. Innovent Biologics
9. Johnson & Johnson
10. Merck
11. Mitsubishi Tanabe Pharma
12. Novartis
13. Novo Nordisk
14. Pfizer
15. Sanofi
16. Sun Pharmaceuticals Industries
17. Teva Pharmaceutical Industries
18. Tonghua Dongbao
19. Viatris (Mylan)
20. Wockhardt
21. Zealand Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Escalating global diabetes prevalence & earlier screening
  • 4.2.2 Rising healthcare expenditures in emerging markets
  • 4.2.3 Strong clinical evidence & guideline endorsements for GLP-1 & SGLT-2 classes
  • 4.2.4 Growing adoption of biosimilar basal insulins
  • 4.2.5 Once-weekly ultra-long-acting basal insulin analogues
  • 4.2.6 Payor-integrated digital therapeutic bundling
• 4.3 Market Restraints
  • 4.3.1 Safety concerns regarding GLP-1-linked pancreatitis & thyroid risks
  • 4.3.2 Public-sector insulin price caps & tender-based procurement
  • 4.3.3 Affordability gaps in low- and middle-income countries
  • 4.3.4 Cold-chain integrity risk in last-mile delivery across tropical regions
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Outlook
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug Class
  • 5.1.1 Oral Anti-Diabetic Drugs
    • 5.1.1.1 Biguanides
    • 5.1.1.2 Alpha-glucosidase Inhibitors
    • 5.1.1.3 Dopamine-D2 Receptor Agonists
    • 5.1.1.4 SGLT-2 Inhibitors
      • 5.1.1.4.1 Canagliflozin (Invokana)
      • 5.1.1.4.2 Empagliflozin (Jardiance)
      • 5.1.1.4.3 Dapagliflozin (Farxiga/Forxiga)
      • 5.1.1.4.4 Ipragliflozin (Suglat)
    • 5.1.1.5 DPP-4 Inhibitors
      • 5.1.1.5.1 Sitagliptin (Januvia)
      • 5.1.1.5.2 Saxagliptin (Onglyza)
      • 5.1.1.5.3 Linagliptin (Tradjenta)
      • 5.1.1.5.4 Alogliptin (Nesina/Vipidia)
      • 5.1.1.5.5 Vildagliptin (Galvus)
    • 5.1.1.6 Sulfonylureas
    • 5.1.1.7 Meglitinides
  • 5.1.2 Insulin
    • 5.1.2.1 Basal / Long-acting
      • 5.1.2.1.1 Insulin Glargine (Lantus, Toujeo, Basaglar)
      • 5.1.2.1.2 Insulin Detemir (Levemir)
      • 5.1.2.1.3 Insulin Degludec (Tresiba)
    • 5.1.2.2 Bolus / Fast-acting
      • 5.1.2.2.1 Insulin Aspart (NovoRapid/Novolog)
      • 5.1.2.2.2 Insulin Lispro (Humalog)
      • 5.1.2.2.3 Insulin Glulisine (Apidra)
    • 5.1.2.3 Traditional Human Insulin
      • 5.1.2.3.1 Novolin / Actrapid / Insulatard
      • 5.1.2.3.2 Humulin
      • 5.1.2.3.3 Insuman
    • 5.1.2.4 Biosimilar Insulin
      • 5.1.2.4.1 Insulin Glargine Biosimilars
      • 5.1.2.4.2 Human Insulin Biosimilars
    • 5.1.2.5 Ultra-long-acting weekly analogues
  • 5.1.3 Non-Insulin Injectable Drugs
    • 5.1.3.1 GLP-1 Receptor Agonists
      • 5.1.3.1.1 Liraglutide (Victoza)
      • 5.1.3.1.2 Exenatide (Byetta, Bydureon)
      • 5.1.3.1.3 Dulaglutide (Trulicity)
      • 5.1.3.1.4 Lixisenatide (Lyxumia)
    • 5.1.3.2 Dual & Triple Incretin Co-agonists
      • 5.1.3.2.1 Tirzepatide (Mounjaro)
      • 5.1.3.2.2 Retatrutide (Phase III)
    • 5.1.3.3 Amylin Analog
  • 5.1.4 Combination Drugs
    • 5.1.4.1 Combination Insulin
      • 5.1.4.1.1 Biphasic Insulin Aspart (NovoMix)
      • 5.1.4.1.2 Insulin Degludec + Aspart (Ryzodeg)
      • 5.1.4.1.3 Insulin Degludec + Liraglutide (Xultophy)
    • 5.1.4.2 Oral Combination
      • 5.1.4.2.1 Sitagliptin + Metformin (Janumet)
      • 5.1.4.2.2 Empagliflozin + Metformin (Synjardy)
• 5.2 By Route of Administration
  • 5.2.1 Oral
  • 5.2.2 Subcutaneous
  • 5.2.3 Intravenous
• 5.3 By Distribution Channel
  • 5.3.1 Online Pharmacies
  • 5.3.2 Hospital Pharmacies
  • 5.3.3 Retail Pharmacies
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 AstraZeneca
  • 6.3.2 Biocon
  • 6.3.3 Boehringer Ingelheim
  • 6.3.4 Bristol Myers Squibb
  • 6.3.5 Eli Lilly and Company
  • 6.3.6 Gan & Lee Pharmaceuticals
  • 6.3.7 Hanmi Pharmaceutical
  • 6.3.8 Innovent Biologics
  • 6.3.9 Johnson & Johnson (Janssen)
  • 6.3.10 Merck & Co.
  • 6.3.11 Mitsubishi Tanabe Pharma
  • 6.3.12 Novartis
  • 6.3.13 Novo Nordisk
  • 6.3.14 Pfizer
  • 6.3.15 Sanofi
  • 6.3.16 Sun Pharmaceutical Industries
  • 6.3.17 Teva Pharmaceuticals
  • 6.3.18 Tonghua Dongbao
  • 6.3.19 Viatris (Mylan)
  • 6.3.20 Wockhardt
  • 6.3.21 Zealand Pharma

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment